Countdown to a possible new drug approval for kidney cancer

Just got word from a Genentech spokesperson that the company expects to hear by the end of this week whether the FDA will approve Avastin for metastatic kidney cancer. (Check out the kidney cancer feature in our current issue.)We'll keep you posted.